Evidence map›Paper›PMID 33803522›Full record

ArticleCancers2021

Supplemental

Felix Bicu, Johann S Rink, Matthias F Froelich, Clemens C Cyran, Johannes Rübenthaler, Emrullah Birgin, Manuel Röhrich, Fabian Tollens

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Felix BicuDepartment of Nuclear Medicine, University Hospital Heidelberg, D-68120 Heidelberg, Germany.
Johann S RinkDepartment of Radiology and Nuclear Medicine, University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, D-68167 Mannheim, Germany.ORCID 0000-0002-7069-5181
Matthias F FroelichDepartment of Radiology and Nuclear Medicine, University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, D-68167 Mannheim, Germany.ORCID 0000-0001-8501-2147
Clemens C CyranDepartment of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, D-81377 Munich, Germany.ORCID 0000-0001-5630-6242
Johannes RübenthalerDepartment of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, D-81377 Munich, Germany.ORCID 0000-0003-0832-5662
Emrullah BirginDepartment of Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, D-68167 Mannheim, Germany.ORCID 0000-0002-0338-3727
Manuel RöhrichDepartment of Nuclear Medicine, University Hospital Heidelberg, D-68120 Heidelberg, Germany.
Fabian TollensDepartment of Radiology and Nuclear Medicine, University Medical Center Mannheim, Theodor-Kutzer-Ufer 1-3, D-68167 Mannheim, Germany.
Heidelberg University · DELMU Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate detection of malignant transformation and risk-stratification of intraductal papillary mucinous neoplasms (IPMN) has remained a diagnostic challenge. Preliminary findings have indicated a promising role of positron emission tomography combined with computed tomography and

Indexed as

cost-effectivenessIPMNmalignancy detectionPancreas lesionsPET/CT

Identifiers

PMID33803522
PMCPMC8002963
OpenAlexW3138800839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.